Ideal for a wide range of filtration sterilization of pharmaceuticals, vaccines, biological drugs, cell culture media, and difficult-to-filter eye drops!
Supor(R) EBV is a sterilizing filter with a pore size of 0.2 μm. It features a special two-layer structure to enhance protective effects, allowing for efficient and economical filtration. Additionally, the use of hydrophilic polyethersulfone (PES) membranes results in very low adsorption of proteins and preservatives, which is also characterized by a high recovery rate of the target substances. 【Features】 - Excellent flow characteristics with a wide membrane area due to the ultra-pleated structure [U.S. Patent No. 5543047]. - Adoption of a two-layer structure combined with an asymmetric pre-layer to maximize protective effects. - Low adsorption performance and broad chemical resistance. - Improved differential pressure during SIP compared to conventional products. - Enhanced cumulative sterilization time by autoclaving compared to conventional products. *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 - Complies with sterilization filter requirements of FDA and GMP - Passes the latest version of USP biological plastic safety testing (Class VI) - Meets USP standards for particle cleanliness and endotoxin in injectable preparations - Complies with non-fiber release requirements of 21 CFR *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
